MenACWY Vaccine Clinical Trial Safety Data

How were meningococcal conjugate vaccines tested before approval? This page documents the pre-licensure clinical trial safety data for every MenACWY vaccine licensed in the United States.

Clinical trial data for the meningococcal conjugate vaccines on the US schedule. The licensure chain contains the most remarkable example of circular licensing in the entire schedule: the same clinical trial was used to certify the safety of both Menomune (as a control) and Menactra (as the test vaccine). Menomune's own FDA-approved package insert references the Menactra trial as evidence of Menomune's safety — meaning a single study simultaneously established the "baseline" and the "new product."

Menomune (Sanofi) — MPSV4

Source: Menomune FDA-approved package insert.

Circular Licensing

The safety section of Menomune's own FDA-approved package insert references the Menactra trial as evidence of Menomune's safety. This means the same clinical trial was used to:

• Establish Menomune as a safety baseline (by serving as the "control" in the Menactra trial)
• License Menactra (as the test vaccine in the same trial)

Aaron Siri: "This is not something I would have ever thought to dream up." One trial — one set of participants, one monitoring period, one sponsor — simultaneously certified the safety of both the control product and the test product. Neither has an independent safety validation.

Menactra (Sanofi) — MCV4

Source: FDA-approved package insert; Sanofi licensure submission.

Menveo (GSK) — MCV4

Source: FDA-approved package insert; GSK licensure submission.

Menveo was licensed as "as safe as" Menactra and Menomune — both of which are party to the circular licensing described above.

MenQuadfi (Sanofi) — MCV4

Source: FDA-approved package insert; Sanofi licensure submission.

Penbraya (Pfizer) — MenABCWY Combination

Source: FDA-approved package insert.

The Complete MenACWY Pyramid

```

Menomune (1981) — no placebo trial

↓ used as control for

Menactra (2005) — Menomune's package insert cites this trial for its own safety

↓ used (with Menomune) as control for

Menveo (2010)

↓ used (with Menactra) as control for

MenQuadfi (2020)

↓ used (with Trumenba) as control for

Penbraya

```

Five levels of "as safe as" comparisons. None anchored to a placebo. The foundational 1981 product has its "safety" supported by the same trial that licensed its successor.

Summary Table

Schedule

Disease Context

Neisseria meningitidis causes invasive bacterial disease — bacterial meningitis and septicemia — primarily affecting adolescents and young adults. The disease is rare but has a case fatality rate of approximately 10–15% and leaves 10–20% of survivors with permanent sequelae. The CDC acknowledges that the vaccine "probably" does not prevent asymptomatic carriage and transmission of the bacterium between individuals.

See Also

MenACWY Vaccines (Post-Licensure), Pre-Licensure Safety Testing, Childhood Vaccine Schedule, Herd Immunity, Sanofi, GSK, Pfizer

Frequently Asked Questions

This is the plain-HTML rendering of vaccines/pre-licensure/MenACWY Vaccines.md, served for search engines, AI crawlers, and accessibility tools. The interactive 3D version of this wiki lives at vaccine-safety.org.